ArticleScientific reports2026
Sustainable high-throughput microwell spectrophotometric methods for avapritinib quality control via charge-transfer complexation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Avapritinib (AVA) is a breakthrough targeted therapy as the first potent inhibitor approved for gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations. It lacks convenient analytical methods for routine quality control. This study addresses this gap by developing and validating two novel, green, high-throughput microwell spectrophotometric methods (MW-SPMs) for AVA quantification in pharmaceutical tablets-representing the first employment of charge-transfer complexation for AVA analysis. The methods exploit rapid charge-transfer complex (CTC) formation between AVA (electron donor) and two π-acceptors: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and chloranilic acid (CLA). The reactions, conducted in 96-well plates using only 200 µL total volume, yielded stable colored complexes with absorption maxima at 460 nm and 520 nm for the reactions with DDQ and CLA, respectively. Following ICH-compliant optimization and validation, both methods demonstrate excellent linearity (3.13-100 µg/well for DDQ; 6.25-100 µg/well for CLA), precision (RSD ≤ 1.8%), and accuracy (recoveries: 98.0-101.7%). Job's method confirmed 1:1 stoichiometry, while density functional theory (DFT) uniquely revealed the molecular basis for the stronger binding affinity of DDQ over CLA through dominant π-π stacking and hydrogen-bonding interactions, demonstrating how computational analysis can guide reagent selection in analytical method development. A comprehensive multi-metric sustainability assessment-utilizing ten tools including AES, AGREE, BAGI, RGB, and RAPI-confirmed the methods' excellent greenness (e.g., AES score = 90), superior practicality, and robust analytical performance, achieving a high White Index of 94.2%. With a substantially higher throughput of ~ 500 samples/hour and minimal solvent consumption (200µL/well), the proposed MW-SPMs offers a rapid, sustainable, and cost-effective alternative to conventional chromatographic and spectrofluorimetric techniques for routine pharmaceutical analysis, aligning with multiple United Nations Sustainable Development Goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.